Interferon-α in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Rosti, G ^a   De Vivo, A ^a   Zuffa, E ^a   Baccarani, M ^b,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Chronic myeloid leukemia; Interferon ; Philadelphia chromosome

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; CYTOKINE; RECOMBINANT ALPHA2A INTERFERON;

BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; ITALY; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; HYDROXYUREA; INTERFERON ALFA-2A; ITALY; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030008424     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689-692.
2. Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-alpha in chronic myelogenous leukemia. New England J Med 1986; 314: 1065-1069.
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 1992; 77: 204-214.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
5. Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia. Karyotypic conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymph 1993; 11: 277-280.
6. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
8. Allan NC, Richards SM, Shepherd PCA et al. UK Medical Research Council randomised, multicentre trial of interferon-αn 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
9. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic response in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-538.
10. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern med 1995; 122: 254-261.
11. Schofield JR, Robinson WA, Murphy JR et al. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukaemia. Ann Intern Med 1994; 121: 736-744.
12. Kloke O, Nierderle N, Qiu JY et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993; 83: 399-403.
13. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: cancer and leukaemia group B study 8583. Blood 1993; 82: 2975-2984.
14. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.